This company listing is no longer active
Initiator Pharma Croissance future
Future contrôle des critères 5/6
Informations clés
21.5%
Taux de croissance des bénéfices
25.7%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 45.6% |
| Taux de croissance des recettes | 62.7% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | n/a |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2024 | 33 | -37 | -39 | -39 | 1 |
| 12/31/2023 | 106 | 44 | 51 | 51 | 1 |
| 12/31/2022 | N/A | -46 | -36 | -36 | 1 |
| 3/31/2022 | N/A | -34 | -40 | -40 | N/A |
| 12/31/2021 | N/A | -21 | -34 | -34 | N/A |
| 9/30/2021 | N/A | -16 | -29 | -29 | N/A |
| 6/30/2021 | N/A | -10 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2020 | N/A | -9 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -10 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -7 | -7 | -7 | N/A |
| 6/30/2019 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2019 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2018 | N/A | -10 | -14 | -14 | N/A |
| 9/30/2018 | N/A | -13 | -16 | -16 | N/A |
| 6/30/2018 | N/A | -11 | -14 | -14 | N/A |
| 3/31/2018 | N/A | -10 | -11 | -11 | N/A |
| 12/31/2017 | N/A | -9 | -8 | -8 | N/A |
| 9/30/2017 | N/A | -7 | -4 | -4 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: INIT BTA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Bénéfices vs marché: INIT BTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: INIT BTA is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: INIT BTA's revenue (62.7% per year) is forecast to grow faster than the Swedish market (9.4% per year).
Croissance élevée des revenus: INIT BTA's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if INIT BTA's Return on Equity is forecast to be high in 3 years time